Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (DME)

Next Previous
Trial Profile

A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (DME)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nesvategrast (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors OcuTerra Therapeutics; SciFluor Life Sciences

    • Most Recent Events

    • 19 Oct 2022 Results published in the Ocuterra media release.
    • 19 Oct 2022 According to OcuTerra media release, the company announced the publication of a paper titled The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study in Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina).
    • 01 Oct 2022 Results assessing safety, tolerability, and biological activity of a topical OTT166 eyedrop administered BID for diabetic retinopathy and diabetic macular edema, published in the Ophthalmic Surgery, Lasers & Imaging Retina.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top